Periprocedural anticoagulation management of patients with venous thromboembolism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 3, 2010, Pages 442-448

  McBane, Robert D ^a   Wysokinski, Waldemar E ^a   Daniels, Paul R ^a   Litin, Scott C ^a   Slusser, Joshua ^a   Hodge, David O ^a   Dowling, Nicole F ^b   Heit, John A ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Anticoagulation; Deep vein thrombosis; Pulmonary embolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; COMPRESSION GARMENT; DEATH; DEEP VEIN THROMBOSIS; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; NEOPLASM; PREOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; THROMBECTOMY; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; CARDIOVASCULAR SURGICAL PROCEDURES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREOPERATIVE CARE; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN; WITHHOLDING TREATMENT;

EID: 77649160290     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.199406     Document Type: Article

References (21)

1. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ III. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158: 585-593.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160: 809-815.
4. Kearon C. Kahn SR. Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S-545S.
5. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393-398. (Pubitemid 27081901)
6. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345:165-169.
7. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639. (Pubitemid 36975995)
8. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
9. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J. The Perioperative Management of Antithrombotic Therapy: Am College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133: 299S-339S. (Pubitemid 351894915)
10. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enox-aparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999;84:478-480.
11. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with Low-Molecular-Weight Heparin vs unfrac-tionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest. 2004;125:1642-1650.
12. Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009;119:2920-2927.
13. Douketis JD, Foster GA, Crowther MA. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000;160:3431-3436.
14. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160: 761-768.
15. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984;108:150-158.
16. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
17. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168:63-69.
18. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110:1658-1663.
19. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-1326.
20. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. Colwell CW. Prevention of venous thromboembolism: the Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. June 2008;133:381S-453S.
21. Baglin TP, Brush J, Streiff M. Guidelines on use of vena cava filters. Br J Haematol. 2006;134:590-595.